BIOABioAge Labs, Inc.
Is the business good?
How good a business is BIOA?
BioAge Labs, Inc. spent more than it took in: an operating loss of $106M on $10M of revenue, 12 months to Q2 2026.
Operating loss · on $10M of revenue · 12 months to Q2 2026
- Share count, year on year
- +25%
Share count, year on year · shareholders own a smaller slice than a year ago
Details›
- Operating margin12 months to Q2 2026
- −1026%
- Net margin12 months to Q2 2026
- −912%
- Free cash flow margin
- −851%
- R&D as % of revenue
- 848%
- Revenue, trailing twelve months
- $10M
- Free cash flow, trailing twelve months
- −$88M
- Net income, trailing twelve months
- −$94M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Customers and suppliers
Who buys from BIOA and who it buys from, as the companies report it.
- One customer100%
Share of revenue · FY2025 10-K
None disclosed.
A company has to disclose every customer behind 10% or more of its revenue. Each share comes from the latest annual report of the company that states it and shows on both companies’ pages; BIOA’s own figures are from its FY2025 10-K. Smaller customers and suppliers go unreported.
Drug Manufacturers, Specialty & Generic
The closest names by size in the same industry